Mga Batayang Estadistika
| LEI | 8945002MP2CXKAENWU30 |
| CIK | 1829802 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Sensei Biotherapeutics, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39980 Sensei Bio |
|
| August 5, 2025 |
EX-99.1 Exhibit 99.1 Sensei Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - Full data for Phase 1/2 dose expansion cohort expected by year-end 2025 - - Cash runway into the second quarter of 2026 - BOSTON, MA – August 5, 2025– Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2025 Sensei Biotherapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39980 83-1863385 (State or Other Jurisdiction of Incorporation) (Commis |
|
| July 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 2, 2025 Sensei Biotherapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39980 83-1863385 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| June 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2025 Sensei Biotherapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39980 83-1863385 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| June 13, 2025 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF SENSEI BIOTHERAPEUTICS, INC. Sensei Biotherapeutics, Inc. (the “Company”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify that: FIRST: The name of this corporation is Sensei Biotherapeutics, Inc., and the da |
|
| May 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2025 Sensei Biotherapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39980 83-1863385 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| May 6, 2025 |
Exhibit 99.1 Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress - Favorable clinical data in PD-(L)1 resistant patients - - Dose expansion enrollment complete with full data expected by year-end 2025 - - Cash runway into the second quarter of 2026 - BOSTON, MA – May 6, 2025– Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnolog |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39980 Sensei Bi |
|
| May 6, 2025 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2025 Sensei Biotherapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39980 83-1863385 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| April 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| April 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| March 28, 2025 |
Exhibit 99.1 Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress - Preliminary efficacy data from Phase 1/2 dose expansion cohort show durable responses and tumor shrinkage in a PD-(L)1 resistant “hot” tumor patient population - - Solnerstotug continues to demonstrate a well-tolerated safety and tolerability profile - - Achieved target enrollment in dose |
|
| March 28, 2025 |
Exhibit 4.3 DESCRIPTION OF SENSEI BIOTHERAPEUTICS, INC. CAPITAL STOCK The following description of the capital stock of Sensei Biotherapeutics, Inc. (the “Company,” “we,” “us” or “our”) is a summary and does not purport to be complete. This summary is qualified in its entirety by reference to the provisions of the Delaware General Corporation Law (the “DGCL”), and the complete text of our amended |
|
| March 28, 2025 |
Exhibit 19.1 SENSEI BIOTHERAPEUTICS, INC. INSIDER TRADING POLICY I. Introduction This policy determines acceptable transactions in the securities of Sensei Biotherapeutics, Inc. (the “Company”) by our employees, directors and consultants. During the course of your employment, directorship or consultancy with the Company, you may receive important information that is not yet publicly available abou |
|
| March 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2025 Sensei Biotherapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39980 83-1863385 (State or Other Jurisdiction of Incorporation) (Commis |
|
| March 28, 2025 |
As filed with the U.S. Securities and Exchange Commission on March 28, 2025 As filed with the U.S. Securities and Exchange Commission on March 28, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SENSEI BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 83-1863385 (State or other jurisdiction of Incorporation or organization |
|
| March 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39980 Sensei Biother |
|
| March 28, 2025 |
Exhibit 3.4 CERTIFICATE OF ELIMINATION OF SERIES A JUNIOR PARTICIPATING CUMULATIVE PREFERRED STOCK OF SENSEI BIOTHERAPEUTICS, INC. Pursuant to Section 151(g) of the General Corporation Law of the State of Delaware Sensei Biotherapeutics, Inc., a Delaware corporation (the “Corporation”), does hereby certify as follows: 1. Pursuant to Section 151(g) of the General Corporation Law of the State of Del |
|
| March 28, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Sensei Biotherapeutics, Inc. |
|
| March 27, 2025 |
Conditionally Active Antibodies for Immuno-oncology March 2025 Exhibit 99.2 Disclaimer This presentation has been prepared by Sensei Biotherapeutics, Inc. (the “Company,” "we," "us") and is made for informational purposes only. The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of |
|
| March 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2025 Sensei Biotherapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39980 83-1863385 (State or Other Jurisdiction of Incorporation) (Commis |
|
| March 27, 2025 |
Exhibit 99.1 Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors – Initial clinical activity in a PD-(L)1 resistant population, with an ORR almost three times higher than historical PD-(L)1 rechallenge response rates, with data still maturing – – One durable complete response in a Merkel Cell Carcinoma (MCC) patient and two partial |
|
| January 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2025 Sensei Biotherapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39980 83-1863385 (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 14, 2024 |
Exhibit 99.1 Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - SNS-101 Phase 1/2 dose expansion clinical data expected in the first half of 2025 - - Organizational restructuring to focus resources on advancing the clinical development of SNS-101 - - Cash runway extended into the second quarter of 2026 - BOSTON, MA – November 14, 2024 – Sensei Biot |
|
| November 14, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2024 Sensei Biotherapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39980 83-1863385 (State or Other Jurisdiction of Incorporation) (Com |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39980 Sense |
|
| November 14, 2024 |
Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”) is entered into as of June 21, 2024 by and between Sensei Biotherapeutics, Inc. (the “Company”) and Josiah Craver (the “Executive”). The Company desires to employ Executive in the capacity of full-time Senior Vice President, Finance pursuant to the terms of this Agreement and, in connection therewith, to compensate Execu |
|
| October 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2024 Sensei Biotherapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39980 83-1863385 (State or Other Jurisdiction of Incorporation) (Comm |
|
| September 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 17, 2024 Sensei Biotherapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39980 83-1863385 (State or Other Jurisdiction of Incorporation) (Co |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39980 Sensei Bio |
|
| August 6, 2024 |
Exhibit 99.1 Sensei Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights - Promising Phase 1/2 SNS-101 clinical data presented at ASCO 2024 - - Enrollment in the Phase 1 dose expansion of SNS-101 clinical trial advancing with initial data on track for Q4 2024 - - Strong balance sheet with cash runway into the fourth quarter of 2025 - BOSTON, MA – August 06, |
|
| August 6, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2024 Sensei Biotherapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39980 83-1863385 (State or Other Jurisdiction of Incorporation) (Commis |
|
| July 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2024 Sensei Biotherapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39980 83-1863385 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| June 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2024 Sensei Biotherapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39980 83-1863385 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| June 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2024 Sensei Biotherapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39980 83-1863385 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| June 3, 2024 |
Conditionally Active Antibodies for Immuno-oncology Corporate Deck | June 2024 Exhibit 99. |
|
| June 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2024 Sensei Biotherapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39980 83-1863385 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| May 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2024 Sensei Biotherapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39980 83-1863385 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| May 23, 2024 |
Exhibit 99.1 Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101 - Once every 3-week dosing of SNS-101 demonstrates initial signs of promising clinical activity - - Pharmacokinetic and safety profile validate conditionally active approach - - Investor webcast to be held on Monday, June 3 at 8:00 a.m. ET - BOSTON, MA – May 23, 2024– Sensei Biotherap |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 Sensei Biotherapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39980 83-1863385 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| May 9, 2024 |
Amended and Restated Non-Employee Director Compensation Policy Exhibit 10.1 Sensei Biotherapeutics, Inc. Non-Employee Director Compensation Policy As Amended and Restated Effective March 5, 2024 Each member of the Board of Directors (the “Board”) who is not also serving as an employee of or consultant to Sensei Biotherapeutics, Inc. (the “Company”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in |
|
| May 9, 2024 |
Exhibit 10.4 AMENDMENT NO. 1 TO SERVICES AGREEMENT This Amendment No. 1 to Services Agreement (the “Amendment”) amends that certain Services Agreement (the “Agreement”), dated April 13, 2023, by and between Sensei Biotherapeutics, Inc. (the “Client”) and Monomoy Advisors, LLC (“Monomoy”). This Amendment shall be effective as of the date all Parties have signed this Amendment. The Client and Monomo |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39980 Sensei Bi |
|
| May 9, 2024 |
Exhibit 10.2 INDEPENDENT CONTRACTOR AGREEMENT THIS INDEPENDENT CONTRACTOR AGREEMENT (together with Exhibit A, the “Agreement”) made as of April 11, 2024 (the “Effective Date”), is between Erin Colgan, having an address at [***] (“Consultant”) and Sensei Biotherapeutics, Inc., having an address at 1405 Research Blvd, Suite 125, Rockville, MD 20850 (“Client”). Client desires to have the benefit of C |
|
| May 9, 2024 |
EX-99.1 Exhibit 99.1 Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights - Completed SNS-101 monotherapy and combination dose escalation through 15mg/kg with no dose limiting toxicities - - Company to present topline clinical data from the SNS-101 Phase 1 dose escalation study at the 2024 ASCO Annual Meeting - - Enrollment in the dose expansion portio |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| April 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2024 Sensei Biotherapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39980 83-1863385 (State or Other Jurisdiction of Incorporation) (Commis |
|
| April 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2024 Sensei Biotherapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39980 83-1863385 (State or Other Jurisdiction of Incorporation) (Commis |
|
| March 7, 2024 |
SNSE / Sensei Biotherapeutics, Inc. / Newtyn Management, LLC Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 2)1 Sensei Biotherapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 81728A108 (CUSIP Number) NEWTYN |
|
| March 5, 2024 |
Exhibit 4.3 SECOND AMENDMENT TO STOCKHOLDER RIGHTS AGREEMENT This Second Amendment to Stockholder Rights Agreement (this “Second Amendment”) is made effective as of the 5th day of March, 2024. This Second Amendment is an amendment to the Stockholder Rights Agreement, dated as of March 7, 2023 (the “2023 Rights Agreement”), between Sensei Biotherapeutics, Inc., a Delaware corporation (the “Company” |
|
| March 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2024 Sensei Biotherapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39980 83-1863385 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| February 29, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Sensei Biotherapeutics, Inc. |
|
| February 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39980 Sensei Biother |
|
| February 29, 2024 |
Incentive Compensation Recoupment Policy, adopted on October 2, 2023. Exhibit 97 Sensei Biotherapeutics, Inc. Incentive Compensation Recoupment Policy 1. Introduction The Compensation Committee (the “Compensation Committee”) of the Board of Directors (the “Board”) of Sensei Biotherapeutics, Inc., a Delaware corporation (the “Company”), and the Board have determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensat |
|
| February 29, 2024 |
Employment Agreement, dated October 19, 2023, by and between the Registrant and Stephanie Krebs. Exhibit 10.10 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”) is entered into as of October 19, 2023 by and between Sensei Biotherapeutics, Inc. (the “Company”) and Stephanie Krebs (the “Executive”). This Agreement amends, restates, and supersedes in its entirety the Term Sheet between the Company and Executive dated September 28, 2023 (the “Prior Agreement”). The Company desires |
|
| February 29, 2024 |
As filed with the U.S. Securities and Exchange Commission on February 29, 2024 As filed with the U.S. Securities and Exchange Commission on February 29, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SENSEI BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 83-1863385 (State or other jurisdiction of Incorporation or organizat |
|
| February 28, 2024 |
Exhibit 99.1 Sensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights - Updated dose escalation data from SNS-101 clinical study supports favorable and potentially best-in-class safety and PK profile both as monotherapy and in combination with PD-1 blockade - - Topline efficacy and biomarker data for both monotherapy and combination arms of dose escalation stu |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2024 Sensei Biotherapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39980 83-1863385 (State or Other Jurisdiction of Incorporation) (Com |
|
| February 13, 2024 |
SNSE / Sensei Biotherapeutics, Inc. / Newtyn Management, LLC Activist Investment SC 13D/A 1 formsc13da.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 1)1 Sensei Biotherapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 81728A |
|
| February 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 5, 2024 Sensei Biotherapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39980 83-1863385 (State or Other Jurisdiction of Incorporation) (Comm |
|
| January 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2024 Sensei Biotherapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39980 83-1863385 (State or Other Jurisdiction of Incorporation) (Commi |
|
| January 4, 2024 |
EX-99.1 Conditionally Active Antibodies for Immuno-oncology Corporate Deck | January 2024 Exhibit 99.1 Disclaimer This presentation has been prepared by Sensei Biotherapeutics, Inc. (the “Company,” "we," "us") and is made for informational purposes only. The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39980 Sense |
|
| November 7, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2023 Sensei Biotherapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39980 83-1863385 (State or Other Jurisdiction of Incorporation) (Comm |
|
| November 7, 2023 |
Exhibit 99.1 Sensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights - SNS-101 initial Phase 1 clinical data presented at SITC demonstrate potential best-in-class safety and pharmacokinetic profile, with no cytokine release syndrome or dose-limiting toxicities reported - - Phase 1/2 trial of SNS-101 continues to enroll ahead of schedule, with new clinical |
|
| November 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2023 Sensei Biotherapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39980 83-1863385 (State or Other Jurisdiction of Incorporation) (Comm |
|
| November 3, 2023 |
EX-99.2 3 ex992to13d10820snse11032023.htm JOINT FILING AGREEMENT, DATED NOVEMBER 3, 2023 Exhibit 99.2 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including amendments thereto) with respect to the Common Stock, $0.0001 |
|
| November 3, 2023 |
begin 644 ex991to13d10820snse11032023.pdf M)5!$1BTQ+C,*)>+CS],*,2 P(&]B:@H\/ HO0W)E871I;VY$871E("A$.C(P M,C,Q,#(U,38R,3(X+3 U)S P)RD*+T-R96%T;W(@*%!&52!38V%N4VYA<"!- M86YA9V5R(#7!E("]#871A;&]G"CX^"F5N9&]B:@HS(# @;V)J"CP\"B],96YG=&@@ M,S T, HO4W5B='EP92 O6$U,"B]4>7!E("]-971A9&%T80H^/@IS=')E86T* M/#]X<&%C:V5T(&)E9VEN/2+ON[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C M>FMC.60B/SX*/'@Z>&UP;65T82!X;6QN#IX;7!T:ST |
|
| November 3, 2023 |
Exhibit 99.1 Sensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual Meeting - Clinical dose escalation data for SNS-101 monotherapy show well tolerated safety profile, potentially best-in-class pharmacokinetics, and encouraging cytokine release profile across multiple dose cohorts - - First VISTA-blocking antibody administered at a dose anticipated to be therapeutic |
|
| November 3, 2023 |
SNSE / Sensei Biotherapeutics Inc / Newtyn Management, LLC - THE SCHEDULE 13D Activist Investment SC 13D 1 sc13d10820snse11032023.htm THE SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. )1 Sensei Biotherapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of C |
|
| November 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2023 Sensei Biotherapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39980 83-1863385 (State or Other Jurisdiction of Incorporation) (Comm |
|
| November 3, 2023 |
Conditionally Active Antibodies for Immuno-oncology NOVEMBER 2023 | Nasdaq: SNSE Exhibit 99. |
|
| October 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2023 Sensei Biotherapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39980 83-1863385 (State or Other Jurisdiction of Incorporation) (Comm |
|
| August 17, 2023 |
Up to $7,371,339 of Shares Common Stock 424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-263567 AMENDMENT NO. 1 DATED August 17, 2023 to Prospectus dated May 9, 2022 Up to $7,371,339 of Shares Common Stock This Amendment No. 1 to Prospectus (this “Amendment”) amends our prospectus dated May 9, 2022 (the “ATM Prospectus”). This Amendment should be read in conjunction with the ATM Prospectus and the accompanying prospectus date |
|
| August 4, 2023 |
SNSE / Sensei Biotherapeutics Inc / Cambrian BioPharma Inc Passive Investment SC 13G/A 1 tm41.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) * Sensei Biotherapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 81728A 108 (CUSIP Number) July 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropri |
|
| August 3, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 Sensei Biotherapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39980 83-1863385 (State or Other Jurisdiction of Incorporation) (Commis |
|
| August 3, 2023 |
Exhibit 99.1 Sensei Biotherapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights Phase 1/2 clinical trial enrolling for lead investigational candidate SNS-101, a conditionally active VISTA- blocking antibody for the treatment of advanced solid tumors A total of 6 patients in three dosing cohorts enrolled to date, with initiation of combination arm now planned for Q4 |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39980 Sensei Bio |
|
| July 10, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2023 Sensei Biotherapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39980 83-1863385 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| June 27, 2023 |
EX-99.1 June 27, 2023 A New Vista for Cancer Care: Exploring SNS-101’s Potential as a Transformative Treatment Option for Patients with Solid Tumors Sensei Presenters: John Celebi Chief Executive Officer Dr. Edward van der Horst Chief Scientific Officer Ron Weitzman Consulting Chief Medical Officer Guest Speaker: James Gulley, M.D., Ph.D., F.A.C.P. Co-Director, Center for Immuno-Oncology Clinical |
|
| June 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2023 Sensei Biotherapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39980 83-1863385 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| June 23, 2023 |
EX-4.2 Exhibit 4.2 AMENDMENT TO STOCKHOLDER RIGHTS AGREEMENT This Amendment to Stockholder Rights Agreement (this “Amendment”) is made effective as of the 23rd day of June, 2023. This Amendment is an amendment to the Stockholder Rights Agreement, dated as of March 7, 2023 (the “Rights Agreement”), between Sensei Biotherapeutics, Inc., a Delaware corporation (the “Company”), and American Stock Tran |
|
| June 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2023 Sensei Biotherapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39980 83-1863385 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| June 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| June 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 5)1 Sensei Biotherapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 81728A108 (CUSIP Number) Julien |
|
| May 23, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2023 Sensei Biotherapeutics, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39980 83-1863385 (State or other jurisdiction of incorporation) (Commissi |
|
| May 23, 2023 |
EX-10.1 Exhibit 10.1 PURCHASE AGREEMENT This PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of May 23, 2023 by and among Sensei Biotherapeutics, Inc., a Delaware corporation (the “Company”), on the one hand, and Apeiron Investment Group Ltd., a Malta private limited company, Presight Sensei Co-Invest Fund, L.P., a Delaware limited partnership, Presight Sensei Co-Invest Managemen |
|
| May 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2023 Sensei Biotherapeutics, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39980 83-1863385 (State or other jurisdiction of incorporation) (Commissi |
|
| May 23, 2023 |
SC 13D/A 1 sc13da41350600205232023.htm AMENDMENT NO. 4 TO THE SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 4)1 Sensei Biotherapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par valu |
|
| May 9, 2023 |
EX-99.1 2 d456403dex991.htm EX-99.1 Exhibit 99.1 Sensei Biotherapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights - Investigational New Drug (IND) application for SNS-101 cleared by U.S. Food and Drug Administration (FDA) with first patient dose in Phase 1/2 trial expected in mid-2023 - - Signing of key collaborations underscore potential of conditional activation |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39980 Sensei Bi |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2023 Sensei Biotherapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39980 83-1863385 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39980 Sensei Bioth |
|
| May 1, 2023 |
Amended and Restated Non-Employee Director Compensation Policy. Exhibit 10.7 Sensei Biotherapeutics, Inc. Non-Employee Director Compensation Policy As Amended and Restated effective April 4, 2022 Each member of the Board of Directors (the “Board”) who is not also serving as an employee of or consultant to Sensei Biotherapeutics, Inc. (the “Company”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in |
|
| April 20, 2023 |
EX-99.1 Conditionally Active Antibodies for Immuno-oncology APRIL 2023 | Nasdaq: SNSE Exhibit 99.1 Disclaimer This presentation has been prepared by Sensei Biotherapeutics, Inc. (the “Company,” "we," "us") and is made for informational purposes only. The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are |
|
| April 20, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 20, 2023 Sensei Biotherapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39980 83-1863385 (State or Other Jurisdiction of Incorporation) (Commis |
|
| March 29, 2023 |
Exhibit 10.13 INDEPENDENT CONTRACTOR AGREEMENT THIS INDEPENDENT CONTRACTOR AGREEMENT (together with Exhibit A, the “Agreement”) made as of December 7, 2022 (the “Effective Date”), is between Doctor Hope LLC, having an address at [***] (“Consultant”) and Sensei Biotherapeutics, Inc., having an address at 451 D Street, Unit 710, Boston, Massachusetts 02210 (“Client”). Client desires to have the bene |
|
| March 29, 2023 |
Exhibit 10.11 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”), is entered into effective as of December 7, 2022 (the “Effective Date”), by and between Sensei Biotherapeutics, Inc. (the “Company”) and Edward van der Horst (the “Executive”). This Agreement amends, restates, and supersedes in its entirety the Employment Agreement between the |
|
| March 29, 2023 |
Exhibit 10.12 December 7, 2022 Robert Pierce, MD [***] Re: Separation from Employment Dear Rob, As previously discussed, your employment with Sensei Biotherapeutics, Inc. shall end effective December 7, 2022 (the “Separation Date”). Pursuant to the conclusion of your employment, please note the following important information: ● You shall receive your final wages through the Separation Date (less |
|
| March 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39980 Sensei Biother |
|
| March 29, 2023 |
As filed with the U.S. Securities and Exchange Commission on March 29, 2023 As filed with the U.S. Securities and Exchange Commission on March 29, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SENSEI BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 83-1863385 (State or other jurisdiction of Incorporation or organization |
|
| March 29, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Sensei Biotherapeutics, Inc. |
|
| March 29, 2023 |
Exhibit 4.3 Exhibit 4.3 DESCRIPTION OF SENSEI BIOTHERAPEUTICS, INC. CAPITAL STOCK The following description of the capital stock of Sensei Biotherapeutics, Inc. (the “Company,” “we,” “us” or “our”) is a summary and does not purport to be complete. This summary is qualified in its entirety by reference to the provisions of the Delaware General Corporation Law (the “DGCL”), and the complete text of |
|
| March 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2023 Sensei Biotherapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39980 83-1863385 (State or Other Jurisdiction of Incorporation) (Commis |
|
| March 28, 2023 |
EX-99.1 Exhibit 99.1 Sensei Biotherapeutics Reports Full Year 2022 Financial Results and Recent Business Highlights - Investigational New Drug (IND) application submitted for lead candidate SNS-101, a conditionally active VISTA-blocking antibody - - New collaborations with Regeneron, the National Cancer Institute and Washington University in St. Louis will support development of SNS-101 - - Compan |
|
| March 13, 2023 |
EX-99.1 Conditionally Active Antibodies for Immuno-oncology MARCH 2023 | Nasdaq: SNSE Exhibit 99.1 Disclaimer This presentation has been prepared by Sensei Biotherapeutics, Inc. (the “Company,” "we," "us") and is made for informational purposes only. The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2023 Sensei Biotherapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39980 83-1863385 (State or Other Jurisdiction of Incorporation) (Commis |
|
| March 10, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Pro |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 Sensei Biotherapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39980 83-1863385 (State or Other Jurisdiction of Incorporation) (Commis |
|
| March 9, 2023 |
APEIRON INVESTMENT GROUP, LTD. 66 Amery Street, SLM1701 Sliema, Malta Exhibit 99.3 APEIRON INVESTMENT GROUP, LTD. 66 Amery Street, SLM1701 Sliema, Malta March 9, 2023 [Nominee] [Address] Re: Sensei Biotherapeutics, Inc. Dear [Nominee]: Thank you for agreeing to serve as a nominee for election to the Board of Directors of Sensei Biotherapeutics, Inc. (the “Company”) in connection with the proxy solicitation that Apeiron Investment Group, Ltd. and certain of its affil |
|
| March 9, 2023 |
APEIRON INVESTMENT GROUP LTD. Beatrice, at 66 & 67 Amery Street, SLM1707 Sliema, Malta Exhibit 99.2 APEIRON INVESTMENT GROUP LTD. Beatrice, at 66 & 67 Amery Street, SLM1707 Sliema, Malta March 9, 2023 [Nominee] [Address] Dear [Nominee]: This letter sets forth our mutual agreement with respect to compensation to be paid to you for your agreement to be named and serve as a nominee of Apeiron Investment Group Ltd. (“Apeiron”) for election as a director of Sensei Biotherapeutics, Inc. ( |
|
| March 9, 2023 |
Exhibit 99.4 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints Julien Hoefer the undersigned’s true and lawful attorney-in-fact to take any and all action in connection with (i) the undersigned’s beneficial ownership of, or participation in a group with respect to, securities of Sensei Biotherapeutics, Inc., a Delaware corporation (the “Company”), d |
|
| March 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 3)1 Sensei Biotherapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 81728A108 (CUSIP Number) Julien |
|
| March 9, 2023 |
Exhibit 99.1 GROUP AGREEMENT WHEREAS, certain of the undersigned are stockholders, direct or beneficial, of Sensei Biotherapeutics, Inc., a Delaware corporation (the “Company”); WHEREAS, Apeiron Investment Group, Ltd. (“Apeiron”) intends to deliver a notice to the Company nominating three candidates for election to the Company’s Board of Directors (the “Board”) at the 2023 annual meeting of stockh |
|
| March 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Sensei Biotherapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 83-1863385 (State or Other Jurisdiction of Incorporation) (IRS Employer Identification No.) 451 D Street |
|
| March 7, 2023 |
Sensei Biotherapeutics Adopts Stockholder Rights Agreement EX-99.1 Exhibit 99.1 Sensei Biotherapeutics Adopts Stockholder Rights Agreement BOSTON, MA, March 7, 2023 – Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer, today announced that a special committee of the Board of Directors adopted a limited duration stockholder rights agreement (the “Rights |
|
| March 7, 2023 |
EX-3.1 Exhibit 3.1 CERTIFICATE OF DESIGNATIONS of SERIES A JUNIOR PARTICIPATING CUMULATIVE PREFERRED STOCK of SENSEI BIOTHERAPEUTICS, INC. SENSEI BIOTHERAPEUTICS, INC. a corporation organized and existing under the General Corporation Law of the State of Delaware (the “Corporation”), in accordance with the provisions of Section 103 thereof, DOES HEREBY CERTIFY: Pursuant to the authority conferred |
|
| March 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2023 Sensei Biotherapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39980 83-1863385 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| March 7, 2023 |
EX-4.1 Exhibit 4.1 SENSEI BIOTHERAPEUTICS, INC. AND AMERICAN STOCK TRANSFER & TRUST COMPANY, LLC AS RIGHTS AGENT STOCKHOLDER RIGHTS AGREEMENT DATED AS OF MARCH 7, 2023 Table of Contents Page Section 1. Certain Definitions 1 Section 2. Appointment of Rights Agent 10 Section 3. Issue of Right Certificates 10 Section 4. Form of Right Certificates 12 Section 5. Countersignature and Registration 14 Sec |
|
| February 14, 2023 |
SNSE / Sensei Biotherapeutics Inc / Cambrian BioPharma Inc Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) * Sensei Biotherapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 81728A 108 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desig |
|
| February 6, 2023 |
Exhibit 99.1 Sensei Biotherapeutics Signs Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to Expand Development Plan for SNS-101, a Conditionally Active VISTA-blocking Antibody BOSTON, February 06, 2023 (GLOBE NEWSWIRE) — Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generatio |
|
| February 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2023 Sensei Biotherapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39980 83-1863385 (State or Other Jurisdiction of Incorporation) (Comm |
|
| December 9, 2022 |
Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF SENSEI BIOTHERAPEUTICS, INC. (A DELAWARE CORPORATION) December 5, 2022 ARTICLE I OFFICES Section 1. Registered Office. The registered office shall be established and maintained at the office of Incorporating Services, Ltd., 3500 South DuPont Highway, in the City of Dover, County of Kent, in the State of Delaware, 19901 and said corporation, or other such |
|
| December 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2022 Sensei Biotherapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39980 83-1863385 (State or Other Jurisdiction of Incorporation) (Comm |
|
| December 8, 2022 |
Exhibit 99.1 Sensei Biotherapeutics Provides Update on Strategic Priorities - Closes Boston research site, reducing workforce by approximately 40 percent to decrease operating expenses - - Continued focus on development of TMAb? programs; IND submission for lead antibody SNS-101 anticipated in or prior to April 2023 - - Cash runway extended into the second half of 2025 - BOSTON, Dec. 8, 2022 (GLOB |
|
| December 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2022 Sensei Biotherapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39980 83-1863385 (State or Other Jurisdiction of Incorporation) (Comm |
|
| November 21, 2022 |
GROUP AGREEMENT WHEREAS, certain of the undersigned are stockholders, direct or beneficial, of Sensei Biotherapeutics, Inc. |
|
| November 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 2)1 Sensei Biotherapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 81728A108 (CUSIP Number) Julien |
|
| November 21, 2022 |
Significant Investor in Sensei Biotherapeutics, Inc. Urges Board to Seek Shareholder Mandate Significant Investor in Sensei Biotherapeutics, Inc. Urges Board to Seek Shareholder Mandate ? Calls for the Board to take immediate action to regain the trust of the shareholders ? Best path forward for Sensei would be to return cash to sharehodlers ? Encourages all other shareholders to reach out to the Board directly to express their views SLIEMA, Malta, Nov. 21, 2022 (GLOBE NEWSWIRE) - Apeiron |
|
| November 10, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 Sensei Biotherapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39980 83-1863385 (State or Other Jurisdiction of Incorporation) (Com |
|
| November 10, 2022 |
Exhibit 99.1 Sensei Biotherapeutics Presents Preclinical Data at the 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting - SNS-101, a highly pH-selective antibody to VISTA, demonstrated anti-tumor effects and promising pharmacokinetic properties in preclinical studies - - Characterization of endogenous expression patterns, and identification of novel T-cell receptors, of VSIG4 enables a |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2022 Sensei Biotherapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39980 83-1863385 (State or Other Jurisdiction of Incorporation) (Comm |
|
| November 8, 2022 |
Conditionally Active Antibodies for Immuno-oncology NOVEMBER 2022 | Nasdaq: SNSE Exhibit 99. |
|
| November 8, 2022 |
Exhibit 99.1 Sensei Biotherapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights - Recent SNS-101 preclinical data demonstrate a favorable pharmacokinetic profile, evidence of advanced anti-tumor effects and a superior cytokine release profile - - New preclinical data on multiple programs to be presented at the Society for Immunotherapy of Cancer (SITC) 37th Annual M |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39980 Sense |
|
| November 2, 2022 |
Exhibit 99.1 Apeiron Investment Group Ltd. Christian Angermayer 66 & 67, Beatrice, Amery Street Sliema, SLM1707 Malta November 2, 2022 Sensei Biotherapeutics, Inc. Board of Directors (the “Board”) 451 D Street, Suite 710 Boston, Massachusetts 02210 Attention: Chairman William Ringo Dear Bill and Members of the Board: I am writing to you on behalf of Apeiron Investment Group Ltd., my private invest |
|
| November 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 1)1 Sensei Biotherapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 81728A108 (CUSIP Number) Julien |
|
| September 30, 2022 |
Exhibit 99.1 Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Sixth Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival - SNS-101 demonstrated a favorable pharmacokinetic profile, enhanced anti-tumor effects in combination with anti-PD-1 antibodies and a significantly improved cyto |
|
| September 30, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2022 Sensei Biotherapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39980 83-1863385 (State or Other Jurisdiction of Incorporation) (Co |
|
| August 31, 2022 |
Exhibit 99.1 Sensei Biotherapeutics Announces New Preclinical Data Demonstrating Favorable Pharmacokinetic and Immunologic Effects of SNS-101, a pH-selective VISTA-blocking Antibody BOSTON, MA ? August 31, 2022 ? Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer, today reported preliminary pre |
|
| August 31, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 31, 2022 Sensei Biotherapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39980 83-1863385 (State or Other Jurisdiction of Incorporation) (Commi |
|
| August 31, 2022 |
Next Generation Immuno-Oncology Medicines John K. Celebi, MBA President & Chief Executive Officer AUGUST 2022 | Nasdaq: SNSE Exhibit 99.2 Disclaimer This presentation has been prepared by Sensei Biotherapeutics, Inc. (the ?Company,? "we," "us") and is made for informational purposes only. The information set forth herein does not purport to be complete or to contain all of the information you may |
|
| August 9, 2022 |
Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (the ?Agreement?), is entered into effective as of June 1, 2022 (the ?Effective Date?), by and between Sensei Biotherapeutics, Inc. (the ?Company?) and Patrick Gallagher (the ?Executive?). This Agreement supersedes in its entirety the offer letter and term sheet between the Company and Executive dated May 5, 2022 (the ?Term Sheet?). The C |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2022 Sensei Biotherapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39980 83-1863385 (State or Other Jurisdiction of Incorporation) (Commis |
|
| August 9, 2022 |
Exhibit 99.1 Sensei Biotherapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights - SNS-101 pre-IND feedback received from FDA with program on track for IND filing in first half of 2023 - - New SNS-101 single dose pharmacokinetic data in non-human primates to be presented in the third quarter of 2022 - - On track with SNS-102 candidate selection, including generation |
|
| August 9, 2022 |
Next Generation Immuno-Oncology Medicines John K. Celebi, MBA President & Chief Executive Officer AUGUST 2022 | Nasdaq: SNSE Exhibit 99.2 Disclaimer This presentation has been prepared by Sensei Biotherapeutics, Inc. (the ?Company,? "we," "us") and is made for informational purposes only. The information set forth herein does not purport to be complete or to contain all of the information you may |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39980 Sensei Bio |
|
| July 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2(a) (Amendment No. )1 Sensei Biotherapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 81728A108 (CUSIP Number) Julien H |
|
| July 19, 2022 |
Joint Filing Agreement, by and among the Reporting Persons, dated July 19, 2022. Exhibit 99.2 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including additional amendments thereto) with respect to the Common Stock, $0.0001 par value per share, of Sensei Biotherapeutics, Inc., a Delaware corporation. |
|
| June 14, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2022 Sensei Biotherapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39980 83-1863385 (State or other jurisdiction of incorporation) (Commiss |
|
| June 10, 2022 |
SNSE / Sensei Biotherapeutics Inc / Cambrian BioPharma Inc Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Sensei Biotherapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 81728A 108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design |
|
| May 10, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Sensei Biotherapeutics, Inc. |
|
| May 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2022 Sensei Biotherapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39980 83-1863385 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| May 10, 2022 |
As filed with the U.S. Securities and Exchange Commission on May 10, 2022 As filed with the U.S. Securities and Exchange Commission on May 10, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SENSEI BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 83-1863385 (State or other jurisdiction of Incorporation or organization) |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q may 10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39980 Se |
|
| May 10, 2022 |
Exhibit 99.1 Sensei Biotherapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights - SNS-101 preclinical data provide encouraging validation of pH-sensitive approach to inhibiting VISTA with high selectivity to treat solid tumors - - Cash runway extended into the first quarter of 2025 with $136.2 million on hand at end of first quarter 2022 - BOSTON, MA ? May 10, 2022 |
|
| May 10, 2022 |
Form of Restricted Stock Unit Grant Notice and Award Agreement under 2021 Equity Incentive Plan. Exhibit 4.5 SENSEI BIOTHERAPEUTICS, INC. RSU AWARD GRANT NOTICE (2021 EQUITY INCENTIVE PLAN) Sensei Biotherapeutics, Inc. (the ?Company?) has awarded to you (the ?Participant?) the number of restricted stock units specified and on the terms set forth below in consideration of your services (the ?RSU Award?). Your RSU Award is subject to all of the terms and conditions as set forth herein and in th |
|
| May 9, 2022 |
As filed with the Securities and Exchange Commission on May 9, 2022 As filed with the Securities and Exchange Commission on May 9, 2022 Registration No. |
|
| May 9, 2022 |
Up to $50,000,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-263567 PROSPECTUS Up to $50,000,000 Common Stock We have entered into an Open Market Sale AgreementSM, or the sales agreement, with Jefferies LLC, or Jefferies, dated March 15, 2022, relating to the sale of shares of our common stock. In accordance with the terms of the sales agreement, pursuant to this prospectus, we may offer and sell shares |
|
| May 6, 2022 |
May 6, 2022 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 4546 Washington, D.C. 20549 Attn: Ms. Celeste Murphy Mr. Michael Davis Re: Sensei Biotherapeutics, Inc. Registration Statement on Form S-3 File No. 333-263567 Withdrawal of Acceleration Request Ladies and Gentlemen: Reference is made to our letter, filed as correspondence via |
|
| May 6, 2022 |
May 6, 2022 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 4546 Washington, D.C. 20549 Attn: Ms. Celeste Murphy Mr. Michael Davis Re: Sensei Biotherapeutics, Inc. Registration Statement on Form S-3 Originally Filed March 15, 2022 File No. 333-263567 Acceleration Request Requested Date: Monday, May 9, 2022 Requested Time: 4:00 P.M. Eas |
|
| May 4, 2022 |
CORRESP 1 filename1.htm May 4, 2022 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 4546 Washington, D.C. 20549 Attn: Ms. Celeste Murphy Mr. Michael Davis Re: Sensei Biotherapeutics, Inc. Registration Statement on Form S-3 Filed March 15, 2022 File No. 333-263567 Acceleration Request Requested Date: Friday, May 6, 2022 Requested Time: |
|
| April 28, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi |
|
| April 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| April 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| April 20, 2022 |
Robert Pierce, MD World Vaccine Congress 2022 Washington, DC Exhibit 99.1 Robert Pierce, MD World Vaccine Congress 2022 Washington, DC SNS-101, A Unique Tumor-selective Anti-VISTA Monoclonal Antibody with a Novel Mechanism of Action Disclaimer This presentation has been prepared by Sensei Biotherapeutics, Inc. (the ?Company,? ?we,? ?us?) and is made for informational purposes only. The information set forth herein does not purport to be complete or to conta |
|
| April 20, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 20, 2022 Sensei Biotherapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39980 83-1863385 (State or Other Jurisdiction of Incorporation) (Commis |
|
| March 15, 2022 |
Form of Common Stock Warrant Agreement and Warrant Certificate. Exhibit 4.4 SENSEI BIOTHERAPEUTICS, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF SENSEI BIOTHERAPEUTICS, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between SENSEI BIOTHERAPEUTICS, INC., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] organized |
|
| March 15, 2022 |
Exhibit 10.12 Sensei Biotherapeutics, Inc. Non-Employee Director Compensation Policy As Amended and Restated effective January 1, 2022 Each member of the Board of Directors (the ?Board?) who is not also serving as an employee of or consultant to Sensei Biotherapeutics, Inc. (the ?Company?) or any of its subsidiaries (each such member, an ?Eligible Director?) will receive the compensation described |
|
| March 15, 2022 |
EXHIBIT 10.14 EXHIBIT 1, SHEET 1 451 D Street Boston, Massachusetts (the ?Building?) Execution Date: January 13 , 20 21 Tenant: Sensei Biotherapeutics, Inc., a Delaware corporation Mailing Address: Prior to Term Commencement Date: Sensei Biotherapeutics, Inc. 1405 Research Boulevard, Suite 125 Rockville, MD 20850 Attention: Erin Colgan, VP of Finance After the Term Commencement Date: 451 D Street |
|
| March 15, 2022 |
Form of Indenture, between the Registrant and one or more trustees to be named. Exhibit 4.2 SENSEI BIOTHERAPEUTICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee?s Certificate |
|
| March 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39980 Sensei Biother |
|
| March 15, 2022 | ||
| March 15, 2022 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate. Exhibit 4.5 SENSEI BIOTHERAPEUTICS, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF SENSEI BIOTHERAPEUTICS, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between SENSEI BIOTHERAPEUTICS, INC., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] o |
|
| March 15, 2022 |
Form of Debt Securities Warrant Agreement and Warrant Certificate. Exhibit 4.6 SENSEI BIOTHERAPEUTICS, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF SENSEI BIOTHERAPEUTICS, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between SENSEI BIOTHERAPEUTICS, INC., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] o |
|
| March 15, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Sensei Biotherapeutics, Inc. |
|
| March 15, 2022 |
Exhibit 21.1 Sensei Biotherapeutics, Inc. Corporate Company Structure Sensei Biotherapeutics, Inc. EIN - 83-1863385 Incorporation State - Delaware 12/1/2017 Sensei Bio Subsidiary, Inc. EIN 52-2166155 Incorporation State - Maryland 4/2/1999 |
|
| March 15, 2022 |
Exhibit 10.10 EMPLOYMENT AGREEMENT This SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the ?Agreement?), is entered into effective as of January 1, 2022 (the ?Effective Date?), by and between Sensei Biotherapeutics, Inc. (the ?Company?) and Erin Colgan (the ?Executive?). This Agreement amends restates, and supersedes in its entirety the Offer Letter between the Company and Executive dated June |
|
| March 15, 2022 | ||
| March 15, 2022 | ||
| March 15, 2022 |
EXHIBIT 10.16 EMPLOYMENT AGREEMENT This SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the ?Agreement?), is entered into effective as of January 1, 2022 (the ?Effective Date?), by and between Sensei Biotherapeutics, Inc. (the ?Company?) and Erin Colgan (the ?Executive?). This Agreement amends restates, and supersedes in its entirety the Offer Letter between the Company and Executive dated June |
|
| March 15, 2022 |
Power of Attorney (included on signature page). Table of Contents As filed with the Securities and Exchange Commission on March 15, 2022 Registration No. |
|
| March 15, 2022 |
Exhibit 10.13 December 1, 2021 Via Electronic Delivery Marie-Louise Fjaellskog, MD, PhD Re: Separation from Employment; Waiver of Non-Competition Provision Dear Marie-Louise: As we have discussed, your employment with Sensei Biotherapeutics, Inc. (the ?Company?) will be concluding on December 5, 2021. With respect to the conclusion of your employment with the Company, please note the following imp |
|
| March 15, 2022 |
Exhibit 4.3 DESCRIPTION OF SENSEI BIOTHERAPEUTICS, INC. CAPITAL STOCK The following description of the common stock of Sensei Biotherapeutics, Inc., or the Company, is a summary and does not purport to be complete. This summary is qualified in its entirety by reference to the provisions of the Delaware General Corporation Law, or the DGCL, and the complete text of the Company?s amended and restate |
|
| March 15, 2022 |
EX-1.2 2 d296045dex12.htm EX-1.2 EXHIBIT 1.2 OPEN MARKET SALE AGREEMENTSM March 15, 2022 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Sensei Biotherapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Age |
|
| March 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2022 Sensei Biotherapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39980 83-1863385 (State or Other Jurisdiction of Incorporation) (Commis |
|
| March 10, 2022 |
EX-99.1 2 d315187dex991.htm EX-99.1 Exhibit 99.1 Sensei Biotherapeutics Reports Full Year 2021 Financial Results and Business Highlights - Reported preclinical proof of concept data from TMAb platform demonstrating potent and selective pH-dependent binding to “active” VISTA - - Initiated 2 new therapeutic programs and IND-enabling studies with SNS-101, a tumor-selective anti-VISTA antibody product |
|
| March 9, 2022 |
EX-99.1 2 d280713dex991.htm EX-99.1 Exhibit 99.1 Sensei Biotherapeutics Appoints William Ringo, MBA, as Chair of Board of Directors - Brings decades of both board and management life sciences experience BOSTON, MA – March 9, 2022 – Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next-generation therapeutics for cancer, today announc |
|
| March 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2022 Sensei Biotherapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39980 83-1863385 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| February 14, 2022 |
SNSE / Sensei Biotherapeutics Inc / H&S INVESTMENTS I LP - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to ? 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to ? 240.13d-2 Under the Securities Exchange Act of 1934 (Amendment No.)* Sensei Biotherapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 81728A108 ( |
|
| February 10, 2022 |
SNSE / Sensei Biotherapeutics Inc / Apeiron Investment Group Ltd. - SC 13G/A Passive Investment United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to ? 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to ? 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Sensei Biotherapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 81728A108 |
|
| January 10, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 Sensei Biotherapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39980 83-1863385 (State or Other Jurisdiction of Incorporation) (Comm |
|
| January 10, 2022 |
Exhibit 99.1 Training the Immune System to Fight Cancer John K. Celebi, MBA President & Chief Executive Officer JP Morgan Healthcare Conference January 10, 2022 NASDAQ: SNSE August ? 2021 Sensei Biotherapeutics. All rights reserved. This presentation has been prepared by Sensei Biotherapeutics, Inc. (the ?Company,? ?we,? ?us?) and is made for informational purposes only. The information set forth |
|
| December 6, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2021 Sensei Biotherapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39980 83-1863385 (State or Other Jurisdiction of Incorporation) (Comm |
|
| December 6, 2021 |
August 4, 2021 Training the Immune System to Fight Cancer December 6, 2021 Exhibit 99. |
|
| November 16, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2021 Sensei Biotherapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39980 83-1863385 (State or Other Jurisdiction of Incorporation) (Com |
|
| November 16, 2021 |
EX-99.1 2 d222516dex991.htm EX-99.1 Exhibit 99.1 VISTA Science Symposium November 16, 2021 Sensei Presenters: Guest Speaker: John Celebi Prof. Robert Schreiber Chief Executive Officer Andrew M. Bursky and Jane M. Bursky Distinguished Professor of Pathology and Immunology, Professor of Molecular Microbiology and co-leader of the tumor Dr. Robert Pierce immunology program at the Siteman Comprehensiv |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39980 Sense |
|
| November 9, 2021 |
Exhibit 99.1 Sensei Biotherapeutics Reports Third Quarter 2021 Results and Recent Business Highlights - SNS-101 identified as a tumor-selective anti-VISTA antibody product candidate from TMAb platform - - SNS-101 preclinical data accepted for presentation at the Society for Immunotherapy of Cancer?s (SITC) 36th Annual Meeting; abstract available online in the Journal for ImmunoTherapy of Cancer - |
|
| November 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2021 Sensei Biotherapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39980 83-1863385 (State or Other Jurisdiction of Incorporation) (Comm |
|
| September 8, 2021 |
August 4, 2021 Training the Immune System to Fight Cancer John K. Celebi, MBA President & Chief Executive Officer September 8, 2021 Exhibit 99.1 This presentation has been prepared by Sensei Biotherapeutics, Inc. (the ?Company,? "we," "us") and is made for informational purposes only. The information set forth herein does not purport to be complete or to contain all of the information you may desi |
|
| September 8, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2021 Sensei Biotherapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39980 83-1863385 (State or Other Jurisdiction of Incorporation) (Com |
|
| August 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39980 Sensei Bio |
|
| August 4, 2021 |
EX-99.1 2 d278782dex991.htm EX-99.1 Exhibit 99.1 Sensei Biotherapeutics Reports Second Quarter 2021 Results and Highlights Recent In Vivo Data from SNS-VISTA Program - Company announced first set of pH-sensitive anti-VISTA antibodies showing significant in vivo anti- tumor activity in combination with PD-1 blockade in a human VISTA knock-in mouse model – - Company plans to select a lead SNS-VISTA |
|
| August 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2021 Sensei Biotherapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39980 83-1863385 (State or Other Jurisdiction of Incorporation) (Commis |
|
| August 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2021 Sensei Biotherapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39980 83-1863385 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| June 28, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2021 Sensei Biotherapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39980 83-1863385 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| June 28, 2021 |
EX-99.1 2 d192052dex991.htm EX-99.1 Exhibit 99.1 Sensei Biotherapeutics Announces Prioritization of Next-Generation Multi-Antigenic ImmunoPhage Platform, Monoclonal Antibody and Nanobody Programs - Company to focus on development of next-generation phage product candidates from ImmunoPhage platform and monoclonal antibody and nanobody programs - - Discontinuation of first-generation, single-antige |
|
| June 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2021 Sensei Biotherapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39980 83-1863385 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| May 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39980 Sensei Bi |
|
| May 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2021 Sensei Biotherapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39980 83-1863385 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| May 12, 2021 |
Exhibit 99.1 Sensei Biotherapeutics Reports First Quarter 2021 Results and Provides Business Update - ImmunoPhage? platform programs and the VISTA program continue to advance - - New safety and efficacy data from ongoing Phase 1/2 combination study of SNS-301 in squamous cell carcinoma of the head and neck accepted for presentation at ASCO 2021? - Patient dosing underway in second cohort of Phase |
|
| May 3, 2021 |
Exhibit 10.1 FIRST AMENDED AND RESTATED EMPLOYMENT AGREEMENT This FIRST AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the ?Agreement?), is entered into effective as of April 28, 2021 (the ?Effective Date?), by and between Sensei Biotherapeutics, Inc. (the ?Company?) and Erin Colgan (the ?Executive?). This Agreement amends, restates, and supersedes in its entirety the Offer Letter between the Company |
|
| May 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2021 Sensei Biotherapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39980 83-1863385 (State or Other Jurisdiction of Incorporation) (Commis |
|
| April 5, 2021 |
EX-99.1 2 d151703dex991.htm EX-99.1 Exhibit 99.1 Sensei Biotherapeutics Appoints Jessie M. English, Ph.D. to its Board of Directors Entrepreneurial leader brings expertise growing biotech platform companies BOSTON, MA and ROCKVILLE, MD – April 5, 2021 – Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), a clinical-stage immunotherapy company focused on the discovery and development of next generation th |
|
| April 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2021 Sensei Biotherapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39980 83-1863385 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| March 30, 2021 |
EX-4.3 2 snse-ex43634.htm EX-4.3 Exhibit 4.3 DESCRIPTION OF SENSEI BIOTHERAPEUTICS, INC. CAPITAL STOCK The following description of the common stock of Sensei Biotherapeutics, Inc., or the Company, is a summary and does not purport to be complete. This summary is qualified in its entirety by reference to the provisions of the Delaware General Corporation Law, or the DGCL, and the complete text of |
|
| March 30, 2021 |
Non-Employee Director Compensation Policy. Exhibit 10.12 Sensei Biotherapeutics, Inc. Non-Employee Director Compensation Policy Each member of the Board of Directors (the ?Board?) who is not also serving as an employee of or consultant to Sensei Biotherapeutics, Inc. (the ?Company?) or any of its subsidiaries (each such member, an ?Eligible Director?) will receive the compensation described in this Non-Employee Director Compensation Policy |
|
| March 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39980 Sensei Biother |
|
| March 25, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2021 Sensei Biotherapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39980 83-1863385 (State or Other Jurisdiction of Incorporation) (Commis |
|
| March 25, 2021 |
EX-99.1 Exhibit 99.1 Sensei Biotherapeutics Reports Full Year 2020 Results and Provides Business Update -Successfully completed upsized IPO in February 2021 raising approximately $152.6 million in gross proceeds – -Large subset of data expected from ongoing Phase 1/2 study of SNS-301 in combination with pembrolizumab for the treatment of locally advanced unresectable or metastatic squamous cell ca |
|
| February 18, 2021 |
EX-99 2 d143453dex99.htm EX-99 Exhibit 99 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that they are jointly filing this statement on Schedule 13G. Each of them is responsible for the timely filing of such statement and any amendments thereto, and for the completeness and accuracy of the i |
|
| February 18, 2021 |
SC 13G United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.)* Sensei Biotherapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 8172 |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Sensei Biotherapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 81728A 108 (CUSIP Number) February 3, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designat |
|
| February 11, 2021 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2021 Sensei Biotherapeutics Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39980 83-1863385 (State or Other Jurisdiction of Incorporation) (C |
|
| February 11, 2021 |
Sensei Biotherapeutics Announces Closing of Initial Public Offering EX-99.1 Exhibit 99.1 Sensei Biotherapeutics Announces Closing of Initial Public Offering BOSTON, MA and ROCKVILLE, MD – February 10, 2021 – Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced the closing of its initial public offering of 7,000,052 shares of its common stock on Febr |
|
| February 11, 2021 |
EX-3.1 2 d95909dex31.htm EX-3.1 Exhibit 3.1 SENSEI BIOTHERAPEUTICS, INC. AMENDED AND RESTATED CERTIFICATE OF INCORPORATION Sensei Biotherapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), does hereby certify as follows: FIRST: That the name of the Company is Sensei Biotherapeutics, Inc. SECOND: That the Company’s original Certificate of In |
|
| February 11, 2021 |
EX-3.2 3 d95909dex32.htm EX-3.2 EXHIBIT 3.2 AMENDED AND RESTATED BYLAWS OF SENSEI BIOTHERAPEUTICS, INC. (A DELAWARE CORPORATION) February 8, 2021 SENSEI BIOTHERAPEUTICS, INC. AMENDED AND RESTATED BYLAWS ARTICLE I OFFICES Section 1. Registered Office. The registered office shall be established and maintained at the office of Incorporating Services, Ltd., 3500 South DuPont Highway, in the City of Do |
|
| February 10, 2021 |
S-8 As filed with the Securities and Exchange Commission on February 10, 2021 Registration No. |
|
| February 4, 2021 |
424B4 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-252183 PROSPECTUS 7,000,052 SHARES COMMON STOCK This is an initial public offering of shares of common stock of Sensei Biotherapeutics, Inc. We are selling 7,000,052 shares of our common stock. The initial public offering price is $19.00 per share. We have granted the underwriters an option for a period of 30 days to pur |
|
| February 3, 2021 |
S-1MEF As filed with the Securities and Exchange Commission on February 3, 2021. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Sensei Biotherapeutics, Inc. (Exact name of Registrant as specified in its charter) Delaware 2834 83-1863385 (State or other jurisdiction of incorporation or or |
|
| February 2, 2021 |
8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(B) OR (G) OF THE SECURITIES EXCHANGE ACT OF 1934 Sensei Biotherapeutics, Inc. |
|
| February 1, 2021 |
Sensei Biotherapeutics, Inc. 2021 Employee Stock Purchase Plan. EX-10.10 Exhibit 10.10 SENSEI BIOTHERAPEUTICS, INC. 2021 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS: JANUARY 27, 2021 APPROVED BY THE STOCKHOLDERS: JANUARY 28, 2021 1. GENERAL; PURPOSE. (a) The Plan provides a means by which Eligible Employees of the Company and certain designated Related Corporations may be given an opportunity to purchase shares of Common Stock. The Plan perm |
|
| February 1, 2021 |
Form of warrant to purchase common stock. EX-4.4 Exhibit 4.4 THE SECURITIES EVIDENCED BY THIS CERTIFICATE HAVE BEEN TAKEN FOR INVESTMENT, HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE SOLD, TRANSFERRED, ASSIGNED, PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF SUCH REGISTRATION OR AN EXEMPTION THEREFROM UNDER SAID ACT. CSW (“Issue Date”) Number of Shares Issuable Upon Exercise: RIGH |
|
| February 1, 2021 |
Form of warrant to purchase common stock. EX-4.3 Exhibit 4.3 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE SOLD, PLEDGED OR OTHERWISE TRANSFERRED EXCEPT IN ACCORDANCE WITH APPLICABLE LAW. WARRANT TO PURCHASE COMMON STOCK Company: SENSEI BIOTHERAPEUTICS, INC. Number of Shares: Class of Stock: Common Stock Warrant Price: $ Issue Date: Expiration Date: THI |
|
| February 1, 2021 |
Amended and Restated Certificate of Incorporation, as currently in effect. EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF SENSEI BIOTHERAPEUTICS, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Sensei Biotherapeutics, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), DOES HEREBY CE |
|
| February 1, 2021 |
Sensei Biotherapeutics, Inc. 2021 Equity Incentive Plan and forms of option agreements thereunder. EX-10.2 Exhibit 10.2 SENSEI BIOTHERAPEUTICS, INC. 2021 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: JANUARY 27, 2021 APPROVED BY THE STOCKHOLDERS: JANUARY 28, 2021 TABLE OF CONTENTS Page 1. GENERAL 1 2. SHARES SUBJECT TO THE PLAN 1 3. ELIGIBILITY AND LIMITATIONS 2 4. OPTIONS AND STOCK APPRECIATION RIGHTS 3 5. AWARDS OTHER THAN OPTIONS AND STOCK APPRECIATION RIGHTS 7 6. ADJUSTMENTS UPON |
|
| February 1, 2021 |
EX-4.1 Exhibit 4.1 Execution Version AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of December 29, 2020, by and among Sensei Biotherapeutics, Inc., a Delaware corporation (the “Company”), each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor” and any A |
|
| February 1, 2021 |
February 1, 2021 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| February 1, 2021 |
Form of warrant to purchase common stock. EX-4.2 Exhibit 4.2 THIS WARRANT AND THE SECURITIES ISSUABLE UPON THE EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF ANY STATES IN THE UNITED STATES. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE ACT AND THE APPLICABLE ST |
|
| February 1, 2021 |
S-1/A Table of Contents As filed with the Securities and Exchange Commission on February 1, 2021. |
|
| February 1, 2021 |
CORRESP 1 filename1.htm 1405 Research Blvd, Suite 125 Rockville, MD 20850 VIA EDGAR February 1, 2021 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 4546 Washington, D.C. 20549 Attn: Ms. Laura Crotty Mr. Tim Buchmiller Ms. Christine Torney Ms. Angela Connell Re: Sensei Biotherapeutics, Inc. Registration Statement on Form S-1 File No. 333-252138 |
|
| February 1, 2021 |
EX-10.13 Exhibit 10.13 SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT This SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”), is entered into effective as of, and contingent upon, the closing of the Company’s initial public offering (the “Effective Date”), by and between Sensei Biotherapeutics, Inc. (the “Company”) and Marie-Louise Fjallskog, MD, PhD (the “Executive”). This Agre |
|
| February 1, 2021 |
EX-10.12 Exhibit 10.12 SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT This SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”), is entered into effective as of, and contingent upon, the closing of the Company’s initial public offering (the “Effective Date”), by and between Sensei Biotherapeutics, Inc. (the “Company”) and John Celebi (the “Executive”). This Agreement amends, restat |
|
| February 1, 2021 |
EX-10.14 Exhibit 10.14 SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT This SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”), is entered into effective as of, and contingent upon, the closing of the Company’s initial public offering (the “Effective Date”), by and between Sensei Biotherapeutics, Inc. (the “Company”) and Robert Pierce, M.D. (the “Executive”). This Agreement amends |
|
| February 1, 2021 |
EX-10.15 Exhibit 10.15 SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT This SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”), is entered into effective as of, and contingent upon, the closing of the Company’s initial public offering (the “Effective Date”), by and between Sensei Biotherapeutics, Inc. (the “Company”) and Anupama Hoey (the “Executive”). This Agreement amends, resta |
|
| February 1, 2021 |
Form of Underwriting Agreement. EX-1.1 Exhibit 1.1 Sensei Biotherapeutics, Inc. [•] Shares Common Stock ($0.0001 par value) Underwriting Agreement [•], 2021 Citigroup Global Markets Inc. Piper Sandler & Co. Berenberg Capital Markets LLC As Representatives of the several Underwriters, c/o Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10013 c/o Piper Sandler & Co. 345 Park Avenue, 12th Floor New York, New Y |
